Gu Anna, Yue Yu, Desai Raj P, Argulian Edgar
From the Department of Pharmacy Administration and Public Health, St. John's University, Queens, NY (A.G., R.P.D.); Paul H. Chook Department of Information Systems and Statistics, Baruch College, City University of New York (Y.Y.); and Division of Cardiology, Mt Sinai St. Luke's Hospital, New York, NY (E.A.).
Circ Cardiovasc Qual Outcomes. 2017 Jan;10(1). doi: 10.1161/CIRCOUTCOMES.116.003166.
A key to reduce and eradicate racial disparities in hypertension outcomes is to understand their causes. We aimed at evaluating racial differences in antihypertensive drug utilization patterns and blood pressure control by insurance status, age, sex, and presence of comorbidities.
A total of 8796 hypertensive individuals ≥18 years of age were identified from the National Health and Nutrition Examination Survey (2003-2012) in a repeated cross-sectional study. During the study period, all 3 racial groups (whites, blacks, and Hispanics) experienced substantial increase in hypertension treatment and control. The overall treatment rates were 73.9% (95% confidence interval [CI], 71.6%-76.2%), 70.8% (95% CI, 68.6%-73.0%), and 60.7% (95% CI, 57.0%-64.3%) and hypertension control rates were 42.9% (95% CI, 40.5%-45.2%), 36.9% (95% CI, 34.7%-39.2%), and 31.2% (95% CI, 28.6%-33.9%) for whites, blacks, and Hispanics, respectively. When stratified by insurance status, blacks (odds ratio, 0.74 [95% CI, 0.64-0.86] for insured and 0.59 [95% CI, 0.36-0.94] for uninsured) and Hispanics (odds ratio, 0.74 [95% CI, 0.60-0.91] for insured and 0.58 [95% CI, 0.36-0.94] for uninsured) persistently had lower rates of hypertension control compared with whites. Racial disparities also persisted in subgroups stratified by age (≥60 and <60 years of age) and presence of comorbidities but worsened among patients <60 years of age.
Black and Hispanic patients had poorer hypertension control compared with whites, and these differences were more pronounced in younger and uninsured patients. Although black patients received more intensive antihypertensive therapy, Hispanics were undertreated. Future studies should further explore all aspects of these disparities to improve cardiovascular outcomes.
减少和消除高血压治疗结果中的种族差异的关键在于了解其成因。我们旨在评估抗高血压药物使用模式以及血压控制方面在种族、保险状况、年龄、性别和合并症存在情况上的差异。
在一项重复横断面研究中,从国家健康与营养检查调查(2003 - 2012年)中识别出8796名年龄≥18岁的高血压患者。在研究期间,所有三个种族群体(白人、黑人及西班牙裔)在高血压治疗和控制方面均有显著改善。白人、黑人及西班牙裔的总体治疗率分别为73.9%(95%置信区间[CI],71.6% - 76.2%)、70.8%(95% CI,68.6% - 73.0%)和60.7%(95% CI,57.0% - 64.3%),高血压控制率分别为42.9%(95% CI,40.5% - 45.2%)、36.9%(95% CI,34.7% - 39.2%)和31.2%(95% CI,28.6% - 33.9%)。按保险状况分层时,黑人(参保者优势比为0.74[95% CI,0.64 - 0.86],未参保者为0.59[95% CI,0.36 - 0.94])和西班牙裔(参保者优势比为0.74[95% CI, 0.60 - 0.91],未参保者为0.58[95% CI,0.36 - 0.94])的高血压控制率持续低于白人。在按年龄(≥60岁和<60岁)和合并症存在情况分层的亚组中,种族差异也持续存在,但在<60岁的患者中差异更为明显。
与白人相比,黑人和西班牙裔患者的高血压控制情况较差,且这些差异在年轻患者和未参保患者中更为显著。尽管黑人患者接受了更强化的抗高血压治疗,但西班牙裔患者治疗不足。未来的研究应进一步探究这些差异的各个方面,以改善心血管疾病治疗结果。